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Development of a protective and broadly-acting vaccine against the most widely distributed human 
malaria parasite, Plasmodium vivax, will be a major step towards malaria elimination. However, a  
P. vivax vaccine has remained elusive by the scarcity of pre-clinical models to test protective efficacy 
and support further clinical trials. In this study, we report the development of a highly protective CSP-
based P. vivax vaccine, a virus-like particle (VLP) known as Rv21, able to provide 100% sterile protection 
against a stringent sporozoite challenge in rodent models to malaria, where IgG2a antibodies were 
associated with protection in absence of detectable PvCSP-specific T cell responses. Additionally, 
we generated two novel transgenic rodent P. berghei parasite lines, where the P. berghei csp gene 
coding sequence has been replaced with either full-length P. vivax VK210 or the allelic VK247 csp 
that additionally express GFP-Luciferase. Efficacy of Rv21 surpassed viral-vectored vaccination using 
ChAd63 and MVA. We show for the first time that a chimeric VK210/247 antigen can elicit high level 
cross-protection against parasites expressing either CSP allele, which provide accessible and affordable 
models suitable to support the development of P. vivax vaccines candidates. Rv21 is progressing to 
GMP production and has entered a path towards clinical evaluation.
Plasmodium vivax malaria poses a major health risk to 2.85 billion people worldwide living in tropical, 
sub-tropical and temperate regions1. P. vivax is the most widely distributed human malaria parasite in the world 
and considered to be the most difficult to control and eliminate from endemic regions. This is largely due to the 
parasite’s ability to remain latent in the liver of infected people to subsequently reactivate, weeks to years after an 
initial infection2,3.
Plasmodium sporozoites enter the blood stream through an infectious mosquito bite and quickly migrate to 
invade the liver. This ‘pre-erythrocytic’ stage is an attractive vaccine target4 used by leading vaccine candidates. 
This includes the most advanced malaria vaccine RTS,S in the adjuvant AS01. This vaccine aims to prevent a 
P. falciparum infection by stimulating immune responses against the major Plasmodium sporozoite surface anti-
gen, circumsporozoite protein (CSP). RTS,S/AS01 has undergone extensive clinical testing and has been shown 
to induce significant protective immunity against P. falciparum in phase III trials5. The homologous CSP protein 
of P. vivax (PvCSP) is also actively being investigated as a component of a pre-erythrocytic vaccine against P. 
vivax, with particular emphasis on a vaccine that includes the PvCSP VK210 and VK247 central repeats to protect 
against the major strains of P. vivax circulating worldwide6–10.
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The evaluation of the protective efficacy of P. falciparum vaccine candidates and vaccine formulations has 
greatly benefited from immunization-challenges studies performed in clinical trials using wild-type parasites 
in controlled human malaria infection (CHMI) studies6,9,11–14. A similar direct evaluation of vaccines and pro-
tective immunity against P. vivax in CHMI studies has recently been reported7. This has been achieved despite 
the difficulty of working with P. vivax, as this species is difficult to maintain in long-term continuous in vitro 
cultures15–18, and the lack of a safe and effective way to clear latent P. vivax forms (hypnozoites) from the liver. 
While a non-human primate (Aotus) challenge model exists, these monkeys are not widely used, due to their 
limited accessibility, ethical issues and the requirement of splenectomy19,20. A transgenic rodent P. berghei par-
asite has been generated where the type 1 repeat region of PvCSP has been incorporated into the endogenous 
P. berghei CSP, and these parasites have been used to examine the role of monoclonal and polyclonal antibod-
ies and virus-like particles (VLP)-based immunization in protection against a sporozoite infection in mice21,22. 
However, only the repeat region of VK210 has been used and the P. vivax CSP epitopes contained in the regions 
outside of this repeat are absent, thus limiting the use of these parasites in vaccine studies to only those candidates 
with VK210 epitopes within the repeat region.
Here we report the development of two rodent challenge models suitable to assess the protective efficacy of 
different PvCSP-based vaccine candidates. In these transgenic P. berghei parasite lines, PbCSP has been replaced 
with full-length P. vivax VK210 or VK247 CSP. Sporozoites of these transgenic parasites were used to challenge 
mice that were previously immunized with various clinically relevant vaccine candidates, expressing or present-
ing PvCSP that contained regions from VK210 or VK247 or both. An effective approach to generate protective 
immunity against P. falciparum in both animal models and in human volunteers consists of sequential immuni-
zation or heterologous ‘prime-boost’ regimes with different viral-vectored vaccines to achieve high frequencies 
of antigen-specific T-cell responses23,24. A prime-boost regimen for malaria has been well established in both, 
mouse and humans, involving an initial ‘prime’ immunization with the chimpanzee adenovirus 63 (ChAd63) 
expressing a Plasmodium antigen followed by a ‘boosting’ immunization with a modified vaccinia virus Ankara 
(MVA) expressing the same parasite antigen23–25. Using this approach, we tested various chimeric forms of PvCSP 
for efficacy against the transgenic parasites.
We also developed and tested a novel VLP using the Hepatitis B surface antigen platform to present the 
PvCSP antigen, which we called Rv21. VLPs are known to stimulate B cells to induce high antibody titers; indeed 
RTS,S/AS01 uses a similar VLP approach5, which presents a hybrid polypeptide consisting of a portion of the 
P. falciparum CSP repeat and C-terminal regions fused to the amino terminal end of the hepatitis B virus surface 
(HepB-S) protein26. This VLP has a four-fold excess of HBsAg monomers in the VLP, required to allow expression 
of the particle in Saccharomyces yeast. Here we report an improved VLP, called Rv21 expressed in Pichia pastoris. 
This is based on the recent successful use of the corresponding R21 P. falciparum vaccine in pre-clinical (Collins 
et al. submitted) and clinical trials (Venkatraman et al. unpublished). Both R21 and Rv21 comprise only the 
hybrid CS-HBsAg protein in the VLP with no additional HBsAg monomers.
Protective immune responses after vaccination with RTS,S are dependent primarily on antibody responses 
against the CS central repeat region27,28. We tested the efficacy of Rv21 in adjuvant vaccination using the new 
P. berghei-PvCSP challenge models in mice. The formulated Rv21 presents both VK210 and 247 repeats and 
the C-terminal portion of PvCSP on its surface. We show that vaccination with a chimeric VK210/247 antigen 
induces protective immune responses against sporozoites expressing both the PvCSP VK210 or VK247 alleles. 
Moreover, we found that an immunization protocol using Rv21 induced complete, sterile protection against a 
stringent sporozoite challenge, surpassing the efficacy of viral-vectored vaccines expressing a similar PvCSP anti-
gen. This work identifies a highly promising new candidate sporozoite vaccine for P. vivax that provides protec-
tion against the two major allelic types and highlights the potential and utility of the rodent challenge model to 
support the development of an efficacious P. vivax malaria vaccine.
Results
Antigen-specific cellular immune responses are not induced in mice immunized with P. vivax 
circumsporozoite viral-vectored vaccines (PvCSP vv). We first assessed whether viral-vectored 
vaccines (vv) expressing the P. vivax circumsporozoite protein (PvCSP) could induce antigen-specific cellular 
immune responses in inbred or outbred mouse strains. We generated four recombinant adenoviruses from the 
chimpanzee viral-vectored vaccines (ChAd63) and four Modified Vaccinia Ankara (MVA) vv expressing different 
regions of PvCSP (PvCSP vv). The resulting recombinant viruses contained a series of PvCSP expression cassettes 
encoding the PvCSP N- and C-terminal sequences of the Salvador I strain of Plasmodium vivax, including or 
excluding the most common central repeat sequences present in the two major PvCSP alleles VK210 and VK247 
(Fig. 1A)8. First, a set of ChAd63 and MVA vv expressing only the N- and C- terminal sequences and no central 
repeats were generated (NC); a second set of vv contained a series of the most common VK210 repeats8 flanked 
by the same NC sequences (N210C); a third set expressed VK247 repeats flanked by NC (N247C). Finally we 
generated a ChAd63/MVA set expressing a chimeric CSP containing both type of repeats (VK210/247) flanked by 
NC (N210/247C). Groups of mice (n = 6) of four different strains received a homologous ChAd63-MVA prime-
boost at an interval of eight weeks between immunizations. Cellular immune responses in mice were quantified 
two weeks after the final immunization using an ex vivo IFN-γ ELISpot assay by stimulating peripheral blood 
mononuclear cells (PBMCs) with a series of peptide pools designed to assess responses against either N210C or 
N247C (Fig. 1B,C). An initial experiment using the prime-boost regimen in inbred C57Bl/6 mice did not yield 
any positive responses (Fig. 1B,C; upper panel). This prompted the assessment of responses in additional mouse 
strains immunized using the same vaccination scheme. None of these other mouse strains (C3H/He, BALB/c or 
outbred CD1) showed detectable antigen-specific T cell responses (Fig. 1B,C) and we concluded that the PvCSP 
molecules that we used in our vv do not have immunodominant T cell epitopes in the animal models tested under 
our experimental conditions. These results are in agreement with earlier observations using a similar vaccine 
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Figure 1. Cellular immune responses following immunization with viral-vectored vaccines (vv; ChAd63 or 
MVA) expressing different versions of PvCSP. (A) Schematic representation of the CSP sequences expressed 
by ChAd63 and MVA vectors. NC: the amino (N)- and carboxyl-terminal (C)- sequences without central repeat 
regions (CR); N210C: a fragment containing the amino (N)- and carboxyl-terminal (C)- sequences flanking 
the VK210 allele; N247C: a fragment containing the amino (N)- and carboxyl-terminal (C)- sequences flanking 
the VK247 allele; N210/247CR:. a fragment containing the amino (N)- and carboxyl-terminal (C)- sequences 
flanking a chimeric fragment with both repeat sequences of the VK210 and VK247 central repeats, all contain 
an insertion region (IR); (B) Groups of mice of four strains (C57Bl6, C3H/HE, BALB/c, CD1, n = 6–8) were 
immunized with different vv using an Ad prime- and MVA boost regimen at an interval of 8 weeks and cellular 
responses were assessed by ex vivo IFN-γ ELISpot on week two after the MVA boost.
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candidate expressing PvCSP9. Nevertheless, splenic follicular T helper cells (Tfh) could be playing a role to sup-
port the generation of PvCSP-specific antibody responses and would deserve further exploration.
Humoral immune responses are induced in mice immunized with the PvCSP vv. We next 
assessed antibody responses induced by the ChAd63 and MVA vaccination protocols described above, using 
CD-1 mice. Serum samples were collected fortnightly up until week 16 after the first immunization. We observed 
that immunization with the vv expressing the chimeric construct N210/247C induced antibody responses to 
both VK210 and the VK247 PvCSP (Fig. 2, top panel). In contrast responses after an immunization with ChAd63 
vv encoding only N210C or N247C, elicited antibodies only against their cognate version of PvCSP (Fig. 2). 
However, low antibody titres against the heterologous PvCSP allele were detected after a boost with the MVA vv, 
suggesting that several encounters with the antigen may stimulate low levels of cross-reactive antibody responses, 
possibly against the conserved N- and C-terminal domains both having a high level of identity of at least 93% in 
the amino acid sequence. No antibody responses were detected after a ChAd63-MVA immunization with either 
the NC or with vv expressing rodent P. berghei CSP.
P. vivax sporozoites isolated from Mexico (Tapachula, Chiapas) are recognized by mouse anti-
bodies after PvCSP vv vaccination. We investigated whether mouse antibodies raised by immunisation 
with various PvCSP antigens encoded by the vv could recognize CSP on the surface of P. vivax sporozoites col-
lected from mosquitoes in the endemic region of Tapachula, Chiapas29. We performed immunofluorescence 
assays (IFAs) using two types of sporozoites in separate slides (e.g. not as a mixing infection), VK210 and VK247. 
Assays were made using three different sporozoite batches and all yielded similar results. Results shown in Fig. 3 
Figure 2. Antibody responses following a prime-boost immunization with viral-vectored (vv) vaccines 
(ChAd63 followed by MVA) expressing different versions of PvCSP. Outbred CD-1 mice (n = 6) were 
immunized with vv expressing various versions of PvCSP (N210/N247C, N210C, N247C, NC; see Fig. 1) using 
a prime-boost interval of 8 weeks. Control groups were mock-vaccinated with vv expressing P. berghei CSP and 
naive mice were injected with PBS, and did not induce any antibodies. Serum was collected every two weeks and 
antibody titers –total IgG- were quantified using a standardized ELISA against the PvCSP VK210 and VK247 
antigens.
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were obtained using sera from C57Bl/6 mice immunized with ChAd63-MVA expressing different regions of the 
CSP protein as described in Fig. 1a. CD-1 mouse sera yielded similar results (data not shown). Samples were 
collected at week 2 after the final boost immunization (Fig. 3). Serum from immunized mice reacted with both 
sporozoites expressing the VK210 allele (Fig. 3 top panel) and sporozoites expressing the VK247 allele (Fig. 3 
bottom panel). Mouse sera at 1:500 dilution yielded better results than at 1:100 dilutions and fluorescent pat-
tern was homogeneous with various degrees of intensity: weak, medium and strong. All pre-immune serum and 
those from primed AdC63 empty vector and boosted with MVA were negative. The monoclonal antibodies 5D3 
(from tissue supernatant) and 2E10 (5 μ g/ml) were used as positive control for the VK210 and VK247 variants, 
respectively.
Development of a rodent challenge model for assessing protective efficacy of the PvCSP vacci-
nation. In order to assess the in vivo protective efficacy of the P. vivax vaccines, we developed rodent challenge 
models consisting on transgenic P. berghei sporozoites where pbcsp was replaced with either full-length VK210 
pvcsp or VK247 pvcsp. These transgenic parasites were generated using the gene insertion/marker out (GIMO) 
based transfection technology30,31 to generate two Double-step Replacement (DsR) mutants32,33 that resulted in the 
coding sequence (CDS) of P. berghei csp being replaced with the CDS of the pvcsp in a two-step GIMO-transfection 
procedure (Fig. 4). First, the pbcsp coding sequence (CDS) was deleted by replacement with the hdhfr::y-
fcu selectable marker cassette (SM) (Fig. 4, Step 1). Subsequently, in these pbcsp GIMO-deletion parasites the 
pvcsp CDS was inserted into the same locus thereby replacing hdhfr::yfcu with the pvcsp CDS (Fig. 4, Step 2). 
These parasites have the full-length pbcsp CDS replaced with pvcsp and were SM free. In the two transgenic 
parasite lines, PbANKA-PvCS VK210(r)PbCS (line 2196cl1) and PbANKA-PvCS VK247(r)PbCS (line 2199cl1) the 
pvcsp gene is under the control of the pbcsp gene promoter (5′ UTR) and the transcription terminator (3′ UTR) 
regulatory elements. In addition to expressing PvCSP, these transgenic parasites constitutively express the fusion 
GFP::luciferase reporter protein, which permits a determination of parasite liver-loads by real-time in vivo imag-
ing (Fig. 4B). Correct replacement of the pbcsp CDS by the pvcsp CDS in the two transgenic lines was confirmed 
by diagnostic Southern analysis of chromosomes separated by pulsed-field gel electrophoresis and diagnostic 
PCR on genomic DNA (Fig. 4C,D). Immunofluorescence microscopy of sporozoites using anti-P. vivax CSP 
monoclonal antibodies to the repeat region of the VK210 or VK247 proteins confirmed the expression of either 
PvCSP VK210 or VK247 in the two transgenic parasite lines (Fig. 5A,B). The P. berghei CSP-specific monoclo-
nal antibody 3D11 confirmed expression P. berghei CSP in wild-type P. berghei sporozoites but anti-P. berghei 
CSP staining was absent in both PbANKA-PvCS VK210(r)PbCS and PbANKA-PvCS VK247(r)PbCS sporozoites 
(Fig. 5C)34,35.
We next assessed the ability of these two transgenic parasites to produce oocysts and sporozoites since replac-
ing the endogenous csp gene with P. vivax csp could alter these characteristics. Oocyst production in Anopheles 
stephensi of the two transgenic parasite lines was similar to oocyst production of WT P. berghei (Fig. 6A, p = 0.24). 
Similarly, the PbANKA-PvCS VK210(r)PbCS parasites produced salivary gland sporozoites comparable to WT 
parasites. In contrast, the PbANKA-PvCS VK247(r)PbCS parasites showed significant (~30%) reduction in sporo-
zoites production compared to WT P. berghei parasites (Fig. 6B, p < 0.05). The infectivity of sporozoites of both 
transgenic parasites was assessed by determination of the pre-patent period (i.e. the time to 1% parasitaemia) 
after intravenous injection of 2,000 sporozoites in the tail vein of outbred CD-1 mice. All sporozoites were capa-
ble of a liver infection and, moreover, the time to 1% parasitemia was not significantly different between WT, 
PbANKA-PvCS VK210(r)PbCS and PbANKA-PvCS VK247(r)PbCS parasites (6.7, 6.5 and 6.7 days, respectively; 
Fig. 6C,D). Additional direct evidence to confirm that the transgenic sporozoites are as infectious as WT sporo-
zoites was obtained by measuring parasite liver load or burden at 44 hours after infection using in vivo imaging of 
bioluminescence. Ploemen et al. have reported that the analysis of liver infections by whole body imaging shows 
a good correlation with quantitative RT-PCR analysis of extracted livers36. Our in vivo imaging results showed no 
difference in parasite liver loads, i.e. sporozoite infectivity between the transgenic/chimeric lines and wild type 
Figure 3. Immunofluorescence Assay (IFA) to assess CSP antibody reactivity of sera from immunized 
mice on the surface of wild type P. vivax parasites isolated from Chiapas, Mexico. Serum obtained from 
C57Bl/6 mice (n = 6) was incubated with P. vivax VK210 (top panel) or VK247 (bottom panel) sporozoites 
collected from the endemic state of Chiapas, Mexico. Each mouse group was immunized with ChAd63-MVA 
vv expressing homologous PvCSP transgenes (NC, N210C, N247C, N210/247C) and sera obtained on week two 
after the final immunization was used at 1:500 dilution. PBS or monoclonal antibodies with specificity to VK210 
(Mab5D3, 2.5 μ g/ml) or VK247 (Mab2E10, 5 μ g/ml) were used as negative or positive controls, respectively. 
Experiment was made using 6 mice/group and three batches of sporozoites for each sample.
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Figure 4. Cloning strategy for the development of two P. berghei parasite lines expressing P. vivax CSP 
VK210 or VK247. (A) Schematic representation describing the generation of PbANKA-PvCSP(r)PbCSP (2196cl1 
and 2199cl1) chimeric lines. The P. berghei csp (Pbcsp) gene coding sequence (CDS) was replaced by the GIMO 
deletion-construct (construct 1; pL1929) using the positive/negative selectable maker (SM; hdhfr::yfcu) cassette, 
resulting in the generation of the Pbcsp GIMO line (PbANKA-PbCSP GIMO; 2151cl1) after positive selection 
with pyrimethamine. Step 2: The GIMO insertion-construct (construct 2; pL1942 or pL1943) replaced the SM in 
the GIMO line with Pvcsp VK-210 or VK-247 CDS, respectively, after negative selection using 5-fluorocytosine 
(5-FC). (B) Schematic representation of the reporter PbANKA parasite line PbGFP-Luceef1α (676m1cl1), used 
to generate the replacement gene [RG] chimeric parasites. (C) Genotype analysis of Replacement Gene [RG] 
chimeric parasites and their intermediate GIMO mother-line knock out chimeric parasites using Southern 
analysis of chromosomes (chrs) separated by pulsed-field gel electrophoresis (PFGE). Left panel: PbANKA- 
ΔCSP GIMO: 2151 cl1. The correct integration of the SM in the right locus in Chr-4 and replacing the 
endogenous PbCSP gene (PBANKA_040320) was confirmed by using the 3′ UTR Pbdhfr/ts probe. Right panel: 
PbANKA-PvCSP(r)PbCSP: 2196cl1 and 2199cl1. Confirmation of the correct integration of the PvCSP expression 
construct into the GIMO locus by Southern blot. (D) Genotype analysis by diagnostic PCR analysis of chimeric 
parasite lines to confirm the correct integration of both PvCSP VK210 and VK247 antigen expression cassettes. 
Primers sequences used are shown in Table S1, while the expected PCR product sizes and the primer numbers 
are listed in the table beside the Agarose gel image.
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parasites (Fig. 6E,F). Therefore, we concluded that the transgenic P. berghei parasites expressing PvCSP alleles in 
place of PbCSP produce fully infectious sporozoites, which are able to complete liver stage development in mice.
PvCSP central repeat sequences are necessary to induce partial protective efficacy against 
P. berghei PvCSP transgenic parasites. We next determined vaccination efficacy by challenging 
vv-immunized mice with the transgenic P. berghei PvCSP transgenic parasites. These mice were immunized with 
the four different (ChAd63-MVA) PvCSP vv, as described above (Fig. 1A). Protective efficacy in these challenged 
mice was determined by measuring the prepatent period after intravenous injection of 2,000 P. berghei PvCSP 
transgenic sporozoites as described previously25.
Our results indicated that the PvCSP central repeat sequences are necessary to generate protective immunity, 
as immunisations with NC only (i.e. lacking either VK210 or 247 repeat sequences) failed to induce protec-
tive immunity, demonstrated by the prepatent period being similar to mock-immunized mice (Fig. 7A). N210C 
immunisation resulted in partial protection against a challenge with the transgenic parasites expressing VK210, 
producing a significant (p = 0.016) prolonged prepatent period. In contrast, N210C immunization did not delay 
the time to patency of transgenic parasites expressing VK247 (Fig. 7B). Immunisation with the N247C vv did not 
induce protection against the transgenic parasites expressing either VK247 or VK210 (Fig. 7C). However, immu-
nization with the chimeric N210/247 C induced a significant delay in the prepatent period after challenge with 
either transgenic parasites expressing either VK210 (p = 0.007) or VK247 (p = 0.0008), while sterile protection 
in 25% and 16% of mice was achieved after a challenge with VK210 or VK247 transgenic parasites, respectively 
(Fig. 7D).
While significant protective immunity was maintained 12 weeks after immunisation with the N210/247C 
vector as determined by a prolonged prepatent period after challenge with either VK210 (p = 0.005) or VK247 
(p = 0.016) transgenic sporozoites, durable sterile protection was not induced as all mice eventually developed 
a blood stage infection (Fig. 7E). We confirmed the absence of unspecific protection induced by N210/247C vv 
vaccination by challenging mice with wild-type P. berghei sporozoites two weeks after boosting immunization. 
These mice were not protected; protection against wild-type P. berghei sporozoites was only induced in mice after 
a prime-boost (ChAd63-MVA) immunisation regimen with a vv expressing P. berghei CS protein (p = 0.024; 
Fig. 7F). These results demonstrate that immune responses to the central PvCSP repeats are necessary to induce 
protective immune responses against infection, assuming that N- and C-terminal domains in the NC construct 
are conformationally correct. Moreover, a chimeric VK210/247 PvCSP vv containing repeats from both forms of 
PvCSP elicit protective immune responses against sporozoites expressing either VK210 or VK247, which are at 
least equal to if not better than after immunisation with a vaccine consisting of only one allelic variant of PvCSP.
Vaccination with the Rv21 VLP induces high levels of protective immunity in mice. The ability 
to induce antibody-mediated protective immunity using the PvCSP vv and the absence of detectable cellular 
responses led us to develop a Virus-Like Particle (VLP) based vaccine platform that has a greater potential to 
Figure 5. Immunofluorescence assay (IFA) to assess expression of PvCSP on the surface of the transgenic 
sporozoites. Sporozoites from mosquito salivary-glands were stained with anti-PvCSP-210 (MR4) diluted 
200 times, anti-PvCSP-247 (MR4) diluted 200 times, and anti-PbCSP (3D11) diluted 1000 times (3D11 
stock (1000X) concentration was at 10 mg/ml and final working concentration was 10 μ g/ml). Alexa Fluor® 
488-labelled anti-mouse IgG and Hoechst-33342 were also included for the assay. (A) Transgenic parasite line 
2196cl1 expressing the PvCSP VK210; (B) Transgenic parasite line 2199cl1 expressing the PvCSP VK247; (C) 
Wild type P. berghei parasite line 676m1cl1 showing expression of PbCSP.
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generate very potent humoral responses against PvCSP. VLPs are known for their ability to induce remarkably 
rapid, strong and long-lasting high antibody titres, and are a leading vaccine platform not only for malaria5 but 
Figure 6. Fitness and phenotype analyses of two transgenic P. berghei lines expressing PvCSP VK210 
or VK247. Mean of oocysts numbers (A) and salivary gland sporozoites (B) in A. stephensi mosquitoes at 
day 10 and 21, respectively (3 independent experiments; 40 mosquitoes per experiment; error bars show 
standard deviation. (C) Blood-stage parasitaemia (mean + SEM) in mice after intravenous (i.v.) injection of 
2000 sporozoites per mouse. (D) The Kaplan-Meier curves illustrate the time to reach 1% parasitaemia (Tto1) 
in 6 CD1 mice after i.v. injection with 2000 transgenic or wild type sporozoites. Survival analysis was made 
using a Kaplan-Meier Log-rank (Mantel-Cox) test. n.s.: not significant. (E) Parasite liver load in mice upon 
intravenous injection of transgenic and wild type parasites, determined by in vivo imaging of bioluminescence. 
(F) Quantification and comparison of parasite liver load measured as total flux per second.
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Figure 7. Viral-vectored vaccine (vv) efficacy against a challenge with transgenic P. berghei sporozoites 
expressing P. vivax CSP VK210 or VK247. Groups of CD-1 mice (n = 6–10) were immunized with vv 
expressing PvCSP (N210/247C, N210C, N247C, NC; see Fig. 1) using an Ad prime and MVA-boost regimen. A 
vv expressing PbCSP was used as control. Two (A–D,F) or 12 (E) weeks after the boost, mice were challenged 
by intravenous injection of 2,000 transgenic sporozoites expressing PvCSP VK210 or VK247. The Kaplan-Meier 
curves illustrate the time to 1% parasitaemia (A–F). As a control PbCSP or N210/247C immunized mice were 
challenged 2 weeks post-boost with wild type P. berghei sporozoites (F). Statistical analysis was performed using 
the Kaplan-Meier survival curves and P values were calculated using a Kaplan-Meier Log-rank (Mantel-Cox) 
test. Data was obtained from two individual experiments.
www.nature.com/scientificreports/
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also for Human papillomavirus (HPV)37. RTS,S/AS01 is based on the hepatitis B surface antigen virus-like par-
ticle (VLP) platform, genetically-engineered to include the central repeats and carboxyl (C-) terminus (amino 
acids 207–395) of the P. falciparum CSP antigen38. We developed a VLP consisting of the chimeric PvCSP VK210/
VK247 central repeats and the CSP C-terminal sequence fused to the Hepatitis B Surface Antigen (HepB-S) 
gene with a C-terminally placed four amino acid C-tag sequence (Glu-Pro-Glu-Ala). Codon usage of the 
fusion genes was optimized for expression in Pichia pastoris and production of the intracellular fusion protein 
(PvCSP-HepB-S) was assessed in three protease knockout strains and protease wild-type P. pastoris strain using 
a time course study expression. The double knock-out P. pastoris strain for prb1 and pep4 proteases had optimal 
protein expression levels after 108 hours of methanol induction. The presence of the fusion protein PvCSP-HepB S 
was confirmed by Western blot analyses using antibodies against PvCSP VK210, PvCSP VK247 and HepB S 
(Suppl Figure 1A). Presence, size and purity of the Rv21 protein was carried out using a sensitive silver stain 
technique (Fig. 1A and Suppl Figure 1B).
The protocol used for purification of the fusion protein VLP has been used for R21 and involved two steps 
(Collins, Brod et al. Scientific Reports, in press). The first consisted of an affinity purification using a capture select 
C-tag matrix bound to the fusion protein under neutral conditions. In addition to collecting the expected protein 
band corresponding to the PvCSP-HepB S protein, the sample also contained additional proteins. VLP particle 
assembly was detected using transmission electron microscopy (TEM) (Suppl Figure 1B). A subsequent purifi-
cation step was performed by size exclusion chromatography in order to clean up the sample from the other pro-
teins with different molecular size and to remove the high concentration of salts (Elution buffer). A single protein 
band of expected size of the PvCSP-HepB S protein (75 kDa) was visualized using the silver staining technique 
and the TEM showed a more homogeneous population of VLPs having a globular shape with some protuberances 
or spikes on the surface, likely due to the PvCSP protein presence on the surface, as represented in a diagram 
(Fig. 8A,B). The purified Rv21 was used to immunize mice, using a low dose of 0.5 μ g/mouse and employing a 
homologous prime-boost immunization protocol using an interval of one week between immunizations. Rather 
than administering the ASO1 adjuvant, standardly used for RTS,S vaccination, Matrix-M adjuvant (Novavax AB 
Uppsala, Sweden) was used to enhance the immunogenicity and protective efficacy of Rv21. Matrix-M is suitable 
for human use and consists of saponin-based 40 nm particles that can activate and recruit immune cells to the 
draining lymph nodes and spleen39,40. This adjuvant functions by inducing high titres of reactive antibodies sup-
ported by a balanced Th1/Th2 response41.
The protective efficacy of each prime-boost regimen was assessed by challenging the Rv21-immunized CD-1 
mice with a dose of 2000 PbANKA-PvCS VK210(r)PbCS or PbANKA-PvCS VK247(r)PbCS transgenic sporozoites 
(Fig. 8C,D). Protective efficacy in these immunized mice was determined by measuring the prepatent period 
as described above. At the low dose (0.5 μ g/mouse) of the Matrix-M-adjuvanted Rv21 prime-boost immuni-
zation, protective efficacy against challenge with PbANKA-PvCS VK210(r)PbCS sporozoites was 100% and 
against PbANKA-PvCS VK247(r)PbCS sporozoites 90%, as confirmed by the absence of a blood infection 20 days 
after challenge (Fig. 8C,D). In contrast, all mice in the naïve group developed blood stage parasitemia with a 
prepatent period of 4–5 days. In the absence of the Matrix-M adjuvant, immunisation of mice using the VLP 
homologous prime-boost regime still generated sterile immunity in 50% of the VLP-immunized mice chal-
lenged with PbANKA-PvCS VK210(r)PbCS sporozoites (Fig. 8C) and 43% of immunized mice were protected 
against a challenge of PbANKA-PvCS VK247(r)PbCS sporozoites (Fig. 8D). These results indicated the impor-
tance of both the VLP and the adjuvant in inducing protective immune responses with this vaccination regime. 
In addition, our results showed that PvCSP VLP-based vaccination induced higher protective efficacy than the 
viral-vectored vaccine candidates. ELISA analyses of antibody responses to vaccination supported the importance 
of Matrix-M adjuvant to elicit high antibody titres to PvCSP, even after a single (priming) immunisation with 
Rv21 (Suppl Figure 2A,B). A prime-boost regimen with Rv21 in the absence of the Matrix-M adjuvant-induced 
higher titres than those by a single vaccination but still lower compared to the prime-boost regime with the adju-
vant. We concluded that the Rv21 antibody responses benefit from the co-administration of an adjuvant, both in 
a single immunization or a prime-boost regime. Importantly, the antibody titres induced by two doses of Rv21 
in matrix-M were over 100-fold higher than those induced by the viral vectored prime-boost regime (Fig. 2 and 
Suppl Fig 2A).
We tested Rv21 efficacy in C57BL/6, a mouse strain that has previously shown to be highly sensitive to 
a P. berghei sporozoite infection and for which we have previously failed to induce sterile immunity using a 
P. vivax TRAP vaccine candidate42. Immunisation of mice with a Rv21 dose as described above (0.5 μ g) followed 
by a challenge with 2,000 transgenic PbANKA-PvCS VK210(r)PbCS sporozoites failed to show protective efficacy 
(Fig. 8E). However, a 10x increase in the Rv21 dose (5 μ g) showed, for the first time in our hands, complete 
protection in C57BL/6 mice even against a challenge with a higher dose of 5,000 PbANKA-PvCS VK210(r)PbCS 
sporozoites (Fig. 8F). Antibody titres measured as total IgG were associated with protection (Fig. 8G,H) and from 
these, only IgG2a was statistically associated with protection after challenging C57Bl/6 mice (Fig. 8H), while 
none of the other isotypes, such as IgM, IgG1, IgG2b and IgG3 showed any statistical association with protec-
tion (Suppl Figure 2D–F). Rv21 immunization (in Matrix M) induced antibody titres that remained consistently 
high for up to 70 days (Fig. 8J), while the inclusion of Matrix-M adjuvant enhanced antibody avidity with the 
time, as the addition of urea decreased antibody titres by 26.2% when using adjuvant and 100% in its absence 
(Suppl Figure 2C).
Our results indicate that immunization with a chimeric VK210/247 vaccine can induce immunity to the two 
major strains of P. vivax, based on the type of PvCSP central repeats. Moreover, high levels of protective immu-
nity levels can be achieved using a VLP platform in the presence of the Matrix-M adjuvant, even in a mouse strain 
that is difficult to protect against a sporozoite infection.
www.nature.com/scientificreports/
1 1Scientific REPORtS | 7:46482 | DOI: 10.1038/srep46482
Figure 8. Development, immunogenicity and efficacy of the Rv21 virus-like particle (VLP) presenting the 
PvCSPVK210/247 antigen fused to the Hepatitis B Surface antigen. The chimeric construct was expressed 
as a VLP in P. pastoris. (A) Analysis of protein purity using silver staining after two purification rounds, using 
size exclusion chromatography of 10 ng of elution sample (A and B), and visualization of VLPs, by TEM (right 
panel). (B) Diagram showing the proposed structure of Rv21. (C) Protective efficacy of Rv21 in CD-1 mice 
(n = 6) immunized using prime-boost at low doses of 0.5 ug of VLP alone or mixed with Matrix M adjuvant and 
challenged with transgenic sporozoites expressing P. vivax CSP VK210 or (D) VK247. Kaplan-Meier curves 
indicate the time to reach 1% parasitaemia. (E) Protective efficacy in C57Bl/6 mice (n = 6) immunized using 
prime-boost, either a low dose of 0.5 ug or a (F) high dose of 5 ug (right) of Rv21 in presence or absence of 
Matrix M adjuvant (Adj). Challenge of mice vaccinated with 5 ug was increased to 5,000 spz/mouse to increase 
stringency. Mice were challenged with transgenic sporozoites expressing P. vivax CSP VK210 or VK247. The 
Kaplan-Meier curves illustrate the time to 1% parasitaemia. (G) Association and (H) correlation of total IgG 
antibody titers with protective efficacy using data of sera from VK210-challenged C57Bl/6 mice. (I) Association 
of titers of IgG2a with efficacy against pre-erythrocytic malaria. (J,G) Kinetic of the antibody responses in 
presence or absence of the Matrix M adjuvant.
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Discussion
The circumsporozoite protein (CSP) is a leading vaccine target for both P. falciparum and P. vivax vaccines26,43. 
For an effective vaccine based on P. vivax PvCSP it has been suggested that immunity must be generated against 
the two major forms of PvCSP that are circulating around the world8,10,11, encoded by the VK210 and VK247 
alleles, thereby generating protective immunity against the majority of P. vivax parasites circulating worldwide. 
While cellular responses play a role in protective immunity against P. falciparum liver infections23–25, the induc-
tion of strong humoral responses against both P. falciparum and P. vivax appears to be critical to the induction 
of protective immunity after immunization with vaccines based on CSP6,9,12. High and long-lasting IgG titers 
have been reported using a variety of platforms including bacterial-expressed recombinant PvCSP, a hybrid CSP 
molecule as a polypeptide or PvCSP expressed by the chimpanzee adenovirus ChAd63 and a chimeric circum-
sporozoite protein6,11,12. The VK210 central repeat region of PvCSP has been expressed as a virus-like particle 
(VLP) within the loop of the hepatitis B virus core antigen, and both the VLP and a recombinant multi-epitope 
polypeptide rPvCSP-ME elicit long-lasting antibody titers of high intensity and avidity6. Recently, targeting the 
CSP antigen of P. vivax with a recombinant soluble protein VMP001 and the particulate antigen CSV-S,S have 
shown to induce robust humoral and cellular immune responses, especially with the particulate CSV-S,S vac-
cine10, that induced high levels of sterile protection in Aotus nancymaae monkeys, and for which an association 
between antibodies to the central repeat region and protection was observed12.
In this study we describe the induction of humoral responses against PvCSP in the absence of detectable 
ex vivo IFN-γ antigen-specific T cell-mediated immunity, when using either viral vectored (vv) or virus-like 
particles (VLP)-based vaccine platforms encoding the VK210 and/or VK247 PvCSP repeat regions. Importantly, 
we demonstrate that antibodies generated after either a VK210 or VK247 based vv-immunization are able to 
recognize native PvCSP on the surface of P. vivax sporozoites isolated in the field.
In the absence of immune correlates of protection, assessment of the protective efficacy of P. falciparum 
malaria vaccine candidates has relied on determining protective efficacy directly against a parasite infection 
in phase IIb field studies or in controlled human malaria infection (CHMI) trials44,45. Due to technical chal-
lenges, which include the lack of P. vivax in vitro blood-stage cultivation system, evaluating protective efficacy of 
P. vivax candidate antigens in CHMI is difficult. Consequently, evaluation of the protective immunity of P. vivax 
pre-erythrocytic vaccines is more dependent on preclinical evaluation in animal models before proceeding with 
phase I and II trials. Preclinical evaluation of P. vivax pre-erythrocytic vaccine candidates has been performed in 
rodents6,9,11,21,42,46 and non-human primates10,12. However, pre-clinical evaluation of protective efficacy in mon-
keys presents additional difficulties, which include their restricted access, as well as the need to conduct these 
studies only in regions where both, monkeys and P. vivax parasites coincide19,20. These limitations in evaluating 
vaccine efficacy very much reduce the rate at which different P. vivax vaccine candidates are ranked and evalu-
ated, and therefore assessed in clinical trials.
In order to evaluate the protective immunogenicity of our PvCSP vaccine candidates and to rationally prioritize 
vaccine candidates for further clinical development, we developed two novel in vivo challenge models in rodents. 
We generated two transgenic P. berghei parasite lines in which P. berghei CSP has been replaced with full-length 
P. vivax VK210 or VK247 CSP. The use of transgenic P. berghei parasites expressing P. vivax or P. falciparum  
antigens is a practical and affordable option, which can be used in laboratories with access to mouse models. 
Indeed, such models have been previously used to analyze protective immunity has been reported for several 
Plasmodium vaccine antigen candidates such as TRAP, CSP and a transmission-blocking vaccine (TBV)21,22,31,47. 
For example, transgenic P. berghei parasites expressing different forms of P. vivax CSP have been generated 
by Espinosa et al.21 and Mizutani (2014) and used to analyze protective immunity upon vaccination. The first 
study used transgenic parasites expressing a chimeric CSP protein consisting of sequences of both P. berghei and 
P. vivax, whereas the latter study used transgenic parasites expressing the P. vivax CSP corresponding to amino 
acids His24 to Asp351 of the PvCSP(Sal) gene minus its signal sequence and glycosylphosphatidylinositol (GPI) 
anchor. As mentioned, it has been suggested that for P. vivax CSP-based vaccines conferring protection against 
the 2 major isoforms of PvCSP (VK210 and VK247) alleles would be immunologically optimal to recognize and 
confer protection against most P. vivax parasites circulating worldwide11. However, confirmation of this hypoth-
esis has remained elusive in the absence of challenge experiments using parasites that express either the VK210 
or the V247 allele. We therefore decided to replace the complete coding sequence of P. berghei with the coding 
sequence of the two major alleles of PvCSP. Interestingly, PvCSP appears to be able to complement the function 
of PbCSP in the transgenic parasites, both in the mosquito and in liver infection. The VK210-expressing parasite 
produced normal numbers of sporozoites similar to a wild type infection. However, while VK247-expressing 
sporozoites also exhibited wild type hepatic-infectivity this line produced 30% fewer sporozoites, suggesting that 
the exact sequence of the CSP repeat region influences sporozoite formation.
The normal in vivo infectivity of the transgenic PvCSP P. berghei sporozoites make these transgenic parasites 
excellent tools to better analyze protective immune responses induced by novel vaccine platforms that induce 
immunity against PvCSP, and in turn can be used to prioritize vaccine candidates for clinical assessment. Using 
these parasites we were able to confirm that epitopes present within the repeat regions are required to confer 
cross-protection against parasites expressing either the VK247 or the VK210 Pvcsp allele. Consequently, we used 
these transgenic parasites to compare different PvCSP vaccination approaches, specifically, ChAd63/MVA viral 
vectored vaccination and a novel Pichia pastoris-expressed Hepatitis B Surface Antigen fusion protein VLP, Rv21. 
While both approaches were able to generate antibody responses against PvCSP, immunization with Rv21 sur-
passed antibody responses by viral vectors and demonstrated very high levels of protective immunity, even in 
hitherto difficult to protect C57BL/6 mice. Prime-boost Rv21 vaccination was able to confer 100% and 90% sterile 
immunity to CD-1 mice challenged with a dose of 2000 VK210 or VK247 expressing transgenic P. berghei sporo-
zoites, respectively. Recently, Whitacre et al.22 have also shown high protective efficacy in C57BL6 mice using an 
E. coli derived VLP that expressed VK210 repeat from PvCSP, this VLP-platform was based on the woodchuck 
www.nature.com/scientificreports/
13Scientific REPORtS | 7:46482 | DOI: 10.1038/srep46482
hepatitis virus core antigen (WHcAg). However in order to generate protective immunity they required very high 
doses (100 μ g) of the VLP22. When Rv21 vaccination was combined with Matrix-M as an adjuvant we were able 
to induce very strong protective immunity at VLP doses as low as 0.5 μ g or 5 μ g in CD-1 or C57Bl/6 mice, respec-
tively. We consider that the use of C57Bl/6 mice is an optimal mouse strain to support vaccine efficacy studies 
through sporozoite challenge experiments, compared to CD-1 mice that are less suited for these studies. This 
adjuvant has been successfully and safely used in humans, most recently for P. falciparum malaria (Venkatraman 
et al. unpublished), and consists of immune-stimulating complexes (ISCOMs) in the form of 40 nm particles 
made with adjuvant-active saponins (Quillaja saponaria), cholesterol and phospholipids41. Matrix-M has been 
shown to enhance immune responses in humans when combined with influenza or West Nile vaccines39,48. The 
observations on the strong adjuvanting properties of Matrix M upon Rv21 is of particular interest as VLPs based 
on the HepB Surface antigen have previously been considered less immunogenic than those using the HepB core 
antigen22. Our study shows that HepB-S based VLPs can be highly immunogenic and protective, even at low doses 
between 0.5 and 5 μ g. Future studies should address the contribution of the N- and C- termini sequences to the 
protective efficacy of VLP vaccines such as Rv21 and CSV-S,S, the latter containing the N-terminus repeat.
In conclusion, the newly developed transgenic P. berghei parasites expressing PvCSP alleles VK210 and 
VK247 repeats have been highly effective tools that have helped develop and optimize vaccine candidate plat-
forms targeting PvCSP. They have confirmed the value of using immunization strategies that induce immune 
responses against the two major isoforms of PvCSP and show that they can greatly improve protection against 
infection. Moreover, using this testing system we have been able to evaluate a novel VLP-based vaccine candidate, 
Rv21, which consists of a chimeric VK210/247 PvCSP fusion molecule combined with hepatitis B surface antigen, 
and have demonstrated that this vaccine is highly efficacious, conferring high levels of protective immunity even 
in mice that have previously been difficult to protect using another leading P. vivax vaccine candidate, TRAP42. 
Importantly, to our knowledge, this is the first evidence of protection against both sporozoites expressing both 
isoforms of the PvCS, VK210 and VK247. Rv21 has now received support for GMP production and has entered 
a path towards clinical trials.
Materials and Methods
Animals. Female inbred BALB/c (H-2d), C57BL/6 (H-2b) and outbred CD1 (ICR) mice were used for the 
assessment of immunogenicity and protection after challenge. Tuck-ordinary (TO) outbred mice were used for 
parasite production and transmission. Mice were purchased from Harlan (UK). Transgenic parasites were devel-
oped in Leiden University Medical Centre (LUMC) using 6-week old Swiss mice (Charles River).
Immunization of mice. Viral vectors: Mice were primed with simian adenoviral vector 63 (ChAd63) encod-
ing PvCSP at a dose of 1 × 108 infectious units (iu) and 8 weeks later boosted with vaccinia-modified virus strain 
Ankara (MVA) encoding the same transgene at a concentration of 1 × 106 plaque forming unit (pfu) per mouse. 
All viral vector vaccines were administered intramuscularly (i.m.) in endotoxin-free PBS and no adjuvant was 
used for vv immunizations.
Rv21 VLP vaccine: Rv21 was administered in endotoxin-fee PBS mixed with 12 μ g of Matrix M Adjuvant 
(Isconova, Sweden, now Novavax, MD, USA). The Rv21 vaccine was injected intramuscularly at a dose of 
0.5 μ g/mouse in CD1 mice, while C57Bl/6 mice received two doses, 0.5 μ g or 5 ug/mouse in different experiments. 
The vaccination regimen for Rv21 consisted of homologous prime-boost at an interval of one week between 
immunizations.
Ethics statement. All animals and procedures were used in accordance with the terms of the UK Home 
Office Animals Act Project License. Procedures were approved by the University of Oxford Animal Care and 
Ethical Review Committee (PPL 30/2414). Animal experiments performed at LUMC were approved by the 
Animal Experiments Committee of the Leiden University Medical Center (DEC 12042). The Dutch Experiments 
on Animals Act was established under European guidelines (EU directive no. 86/609/EEC regarding the 
Protection of Animals used for Experimental and Other Scientific Purposes).
Parasite production. Wild type and transgenic parasites used to challenge mice were produced at the 
insectary of the Jenner Institute. Female Anopheles stephensi mosquitoes were fed on infected TO mice. Briefly, 
exflagellation was first confirmed and mosquitoes were exposed to anaesthetized infected mice for 10 minutes. 
Mosquitoes were then maintained for 21 days in a humidified incubator at a temperature of 19–21 °C on a 12 hour 
day-night cycle and fed with a fructose/PABA solution.
Parasites. The wild type (WT) reference line cl15cy1 of P. berghei ANKA49 and the reporter PbANKA para-
site line PbGFP-Luccon (676m1cl1). PbGFP-Luccon parasite expresses a fusion protein of GFP (mutant3) and firefly 
luciferase (LUC-IAV) under the constitutive eef1a promoter and is SM free49. The reporter-cassette is integrated 
into the neutral 230p locus (PBANKA_030600). For details of PbGFP-Luccon, see RMgmDB entry #29 (http://
www.pberghei.eu/index.php?rmgm= 29).
Generation of DNA constructs and genotyping of the transgenic parasites. To generate the trans-
genic parasites where the P. berghei csp gene (PBANKA_040320) coding sequence (CDS) has been replaced by the 
CDS of P. vivax csp (PVX_119355), we used a 2-step GIMO transfection protocol31,50. In the first step we deleted 
the P. berghei csp CDS and replaced it with the positive-negative selectable marker, to create a P. berghei csp 
deletion GIMO line (PbANKA-CSP GIMO). In order to this we generated pL1929 construct that is based on the 
standard GIMO DNA construct pL003450. This construct contains the positive-negative (hdhfr::yfcu) selection 
marker (SM) cassette, and was used to insert both the Pbcsp 5′ and 3′ gene targeting regions (TR), encompassing 
the full-length promoter and transcription terminators sequences respectively. The linear pL1929 DNA construct 
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was introduced into PbGFP-Luccon parasites using standard methods transfection49. Transfected parasites were 
selected in mice by applying positive selection by providing pyrimethamine in the drinking water49. Transfected 
parasites were cloned by limiting dilution51, resulting in the PbANKA-CSP GIMO line (2151cl1). Correct deletion 
of the P. berghei csp CDS was confirmed by diagnostic PCR-analysis on gDNA and Southern analysis of pulsed 
field gel (PFG) separated chromosomes as described49. Primers used for PCR genotyping are listed in Table S1.
In the second step we replaced the positive-negative SM in the PbANKA-CSP GIMO genome with the CDS of 
either P. vivax VK210 or VK247 csp by GIMO transfection to create the two P. berghei transgenic CSP replacement 
lines. This was achieved by modifying the construct used in the first step (pL1929); specifically, the hdfhr::yfcu 
SM cassette was removed and replaced with P. vivax csp CDS sequence. The P. vivax csp CDS was ordered from 
GeneArt (Regensburg, Germany) (i.e. VK210) or cDNA (VK247) Both the P. vivax VK210 and VK247 CSP 
constructs (pL1942 and pL1943, respectively) were sequenced to ensure there were no mutations in the P. vivax 
csp CDS. These constructs were linearized using SacI and PacI restriction enzymes outside of the 5′ and 3′ TRs 
before transfection. These constructs were used to transfect parasites of the PbANKA-CSP GIMO line (2151cl1) 
using standard methods of GIMO-transfection30. Transfected parasites were selected in mice by applying nega-
tive selection by providing 5-fluorocytosine (5-FC) in the drinking water of mice52. Negative selection results in 
selection of chimeric parasites where the hdhfr::yfcu SM in the csp locus of PbANKA-CSP GIMO line is replaced 
by the CDS of P. vivax CSP Selected transgenic parasites were cloned by the method of limiting dilution51. Correct 
integration of the constructs into the genome of chimeric parasites was analysed by diagnostic PCR-analysis on 
gDNA and Southern analysis of pulsed field gel (PFG) separated chromosomes as described49. Primers used for 
PCR genotyping are listed in Table S1. This method creates transgenic ‘gene replacement’ P. berghei parasites 
that do not contain P. berghei csp gene CDS but express either P. vivax VK210 (PbANKA-PvCSP VK210(r)PbCS; 
2196cl1) or VK247 csp (PbANKA-PvCSP VK247(r)PbCS; 2199cl1) under the control of the P. berghei csp regula-
tory sequences.
Phenotyping of reporter and transgenic parasites. The growth of blood stages of the reporter 
and transgenic P. berghei parasites was determined during the cloning period as described30,49. Feeding 
of An. stephensi mosquitoes, determination of oocyst production, sporozoite collection were performed 
as described30. Expression of PvCSP-VK210 and PvCSP-VK247 antigens in sporozoites of the transgenic 
parasites was analysed by immunofluorescence- staining assay (IFA), using anti-P. vivax antigen mono-
clonal antibodies (anti-PvCSP-VK210 (MR4) or anti-PvCSP-247 (MR4) antibodies; diluted 200 times) 
or anti-PbCSP 3D11 antibodies as a control; diluted 1000 times. Purified sporozoites were fixed with 4% 
paraformaldehyde in PBS for 20 min on ice, then washed three times with PBS and blocked with 20 ul 
10% FCS + 1% BSA in PBS for 30 min at room temperature. The excess blocking medium was removed, followed 
by the addition of 20–25 uL primary monoclonal antibody in 10% FCS + 1% BSA in PBS (blocking medium) for 
1–2 hours at room temperature or overnight at 4 °C. After incubation the primary antibody was removed and the 
slides washed three times with PBS, followed by the staining with the secondary antibody (Alexa Fluor® 488 Goat 
Anti-Mouse IgG from life technologies, Cat# A-11001) diluted 800 times in 10% FCS + 1% BSA in PBS (block-
ing medium) for 1 hour at room temperature. After washing three times with PBS, nuclei were stained with 2% 
Hoechst-33342 (Cell Signaling Technology #4082S) in PBS for 10 minutes at room temperature, washed twice 
with PBS and left to air-dry, this followed by adding Fluorescence Mounting Medium (Dako, code S3023) before 
complete dry out. Cover slips were mounted onto the slides, and the slides were sealed with nail polish and left 
to dry overnight in dark. The parasites in both blue and green channels were analyzed using a DMI-300B Leica 
fluorescence microscope and images processed using ImageJ software.
Immunofluorescence Assay for Wild-Type P. vivax isolates from Mexico. Antibody recognition to 
native, wild-type P. vivax isolates from Mexico was assessed by IFA using a technique described earlier53. Briefly, 
sporozoites were produced by infection of laboratory-reared An. albimanus mosquitoes that fed on blood from 
patients infected with P. vivax. Mosquitoes were maintained for 15–18 days and sporozoites were collected by 
dissection of the salivary glands and deposited in multiwell IFAT slides at a concentration of 2,000 sporozoites/
well to make individual slides containing P. vivax sporozoites VK210 or slides with only VK247, keeping them 
separate and not as mixed parasites. Confirmation of the VK210 and VK247 variant types was made as described 
earlier54 using primers to amplify the repeat VK210 or VK247 regions followed by slot blot and hybridization to 
32P-labeled oligonucleotide probes for VK210 and VK247 and a final confirmation was made using the monoclo-
nal antibodies 5D3 and 2E10, specific for the VK210 and VK247 variant types. Slides were kept frozen at − 70 °C 
until used. The assay was performed using sera from C57Bl/6 and CD-1 mice, which was incubated with three 
different batches each of sporozoites, yielding similar results between both strains. Air-dried sporozoites were also 
incubated with anti-VK210 (monoclonal antibody 5D3 at 2.5 μ g/ml) or anti-VK247 (monoclonal antibody 2E10 
at 5 μ g/ml) monoclonal antibodies as positive controls29. Slides were analyzed using a confocal microscope and 
titers were calculated using the highest dilution that gave positive fluorescence.
Efficacy studies: Determination of liver parasite liver load by real-time imaging and determination prepatent 
period (after challenge of immunized mice with transgenic sporozoites)
To determine the efficacy of the liver-stage vaccines, transgenic P. berghei infected A. stephensi mos-
quitoes were dissected 21 days post-feed and salivary gland sporozoites resuspended in RPMI-1640 media 
(Sigma-Aldrich). 2000 sporozoites in 100 μ l were injected i.v. into the tail vein per mouse, into both vaccinated 
and naïve controls.
P. vivax CSP DNA sequences. Four versions of ChAd63 and four of MVA were designed and produced to 
express various versions of the P. vivax CSP protein. One consisted of only the N- and C- terminal regions (NC); 
a second viral vector expressed VK210 repeats inserted in between the N- and C-terminal sequences (N210C). 
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A third vector expressed VK247 inserted between the N- and C-terminal sequences (N247C) and a final design 
consisted on a chimeric VK210/247 flanked by similar N- and C-terminal repeats (sequences detailed below).
DNA transgenes were synthesized by GeneArt (Regensburg, Germany) and constructs were previously mod-
ified to improve antigen expression within the hosts cells, modifications included codon optimization for mam-
malian use and replacement of the endogenous PvCSP leading sequence for tPA (human plasminogen activator) 
(GenBank Accession no. K03021). In addition, the transmembrane GPI-anchor domain was removed from the 
Plasmodium vivax circumsporozoite protein (PvCSP) genes to allow protein secretion from any virus-transduced 
cell. The chimeric PvCSP vaccine insert consisted on the N- and C- terminal region from the Salvador I strain 
(NCBI Reference Sequence XP_001613068.1) flanking the central repeat regions of the circumsporozoite (CSP) 
VK210 of the Belem strain (GenBank accession number P08677) or VK247 of the Papua New Guinea (PNG) 
(GenBank accession number M69059.1). The central repeat region was designed using segments of 9 amino 
acid repeats that are most frequently found in Plasmodium vivax as follows: VK210 (5x(GDRAAGQPA), 4x(G-
DRADGQPA), 1x(GNGAGGQAA)) and VK247 (2x(ANGAGNQPG/ANGAGGQAA), 1x(ANGAGDQPG/
ANGAGDQPG), 1x(ANGADDQPG/ANGAGDQPG), 1x(EDGAGNQPG/ANGAGDQPG))8. A region II-plus 
was included in the C-terminal sequence of the vaccine (EWTPCSVTCG)55, as well as an insertion region in the 
C-terminal sequence of PvCSP (GAGGQAAGGNA)56. The VK210 vaccine insert consisted on the Salvador I 
strain sequence, while the VK247 consisted of the PNG sequence with the accession numbers mentioned above. 
A control viral vector lacking the expression of any transgene was used as a control in mock-vaccinated mice.
Viral vector construction. All of DNA constructs required for ChAd63 were cloned in two steps. In the first 
step, unique Acc65I and NotI sites were used to insert the synthetic transgenes into an adenovirus entry plasmid. 
The transgene was placed upstream of BGH poly(A) transcription termination sequence and under the control of 
the long cytomegalovirus (CMV) promoter (containing a regulatory element, an enhancer and an intron A). The 
entry plasmid also contained attachment L (attL) sequences, which were required for site-specific recombination 
with attachment R (attR) sites located on the destination vector.
In the second step of cloning, an in vitro Gateway reaction was performed mediated by LR Clonase II system 
(Invitrogen), whereby the transgene of the entry vector was integrated into the destination plasmid by site-specific 
recombinase through an attL-attR interaction. The diagnostic PCR was performed to confirm the desired integra-
tion before completing the production of the recombinant ChAd63.
Similarly, all of the malarial genes were inserted into an MVA shuttle vector using a similar cloning strategy. 
Unique Acc65I and XhoI sites were used for transgene restriction and ligation and the transgenes were inserted 
under the control of an endogenous P7.5 promoter. PCR and RFLP were used to verify the correct insertion 
before linearization of the MVA plasmid.
Rv21 HepB Surface antigen VLP design and development. A gene containing a chimeric CSP 
sequence comprising the repeat regions VK210 and VK247, followed by the C-terminal sequence (210/247C) 
was designed to be fused to the Hepatitis B surface antigen (HepBsAg) followed C-terminally by the peptide 
EPEA (C-Tag) for affinity purification. The sequence was codon-optimised for optimal expression in yeast and 
purchased from GeneArt® (InVitrogen). DNA sequences were similar to those expressed by recombinant ChAd 
and MVA viruses, but without the N-terminal CSP region. The construct was cloned into the pPink-HC intra-
cellular Pichia plasmid and amplified in E. coli. Upon plasmid linearization, four strains of Pichia pastoris (knock 
out for ade2, ade2-pep4, ade2-prb1, ade2-pep4-prb1) were electroporated and white colonies were selected using 
PAD selection plates. Cultures for protein expression were grown in glycerol containing medium and expression 
was induced by addition of methanol. Growth kinetics were analysed to determine conditions for optimal pro-
tein production The VLPs were purified from yeast lysates by C-Tag affinity chromatography followed by size 
exclusion chromatography. (Collins et al. manuscript in preparation). Fractions from gel filtration were analyzed 
by SDS-PAGE and subsequently transferred to nitrocellulose membranes, blocked in 5% skimmed milk/PBS fol-
lowed by addition of primary and secondary antibodies. VLP-containing fractions from the gel filtration column 
were detected with anti-HBsAg, anti-PvCSP VK210 and anti-PvCSP VK247 primary mouse antibodies, diluted 
in 3% BSA/PBS to 1:200, 1:20,000 and 1:20,000 respectively (MR4). Silver staining was used to analyse purity of 
the fractions from the FPLC column and of progressive stages of the VLP purification process. The samples were 
run on Mini-PROTEAN 12% gels (BioRad) with the Pierce unstained protein ladder (Thermo Scientific) run 
for reference. The gels were subjected to silver staining using a Pierce silver stain kit (Thermo Scientific). Direct 
staining of gels was carried out according to manufacturer’s instructions. The particle-containing fraction from 
the sephacryl gel filtration column was negatively stained with 2% uranyl acetate as follows: the Rv21 sample was 
imaged using a FEI Tecnai 12 Transmission Electron Microscope (TEM). The TEM protocol used to evaluate 
the different Rv21 vaccine purification steps used a FEI Tecnai 12 Transmission Electron Microscope (TEM) at 
an accelerating voltage of 80 kV. The samples (10 μ g) were absorbed for 1 min to a glow-discharged C-Formvar 
coated Cu-grids (300 mesh) and negatively stained with 2% (w/v) uranyl acetate, pH 4.5. The VLPs were visual-
ized taking under 20,000× magnification, and the photographic records were performed on 4 Megapixel Gatan 
Ultrascan™ 1000 CCD camera.
Whole IgG Enzyme-linked immunosorbent assay (ELISA). ELISAs measuring total IgG were car-
ried out as described previously24. Serum antibody endpoint titers were taken as the x-axis intercept of the dilu-
tion curve at an absorbance value three standard deviations greater than the OD405 for serum from a naïve 
mouse. Results were also calculated using a standardized ELISA by including a high-titre reference serum from 
hyper-immune mice to each ELISA plate to produce a standard curve, which in turn was used to quantify and 
assign ELISA units to each sample57. Briefly, Nunc Maxisorp Immuno ELISA plates were coated with the antigens 
diluted in PBS to a final concentration of 1 μ g/mL. Each plate contained a standard curve, negative and positive 
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controls, as well as serum samples of mice pre-boost (1:300) or post-boost (1:3000). An anti-mouse IgG coupled 
to alkaline phosphatase was used as a secondary antibody. Development was made with 4-nitrophenylphosphate 
diluted in diethanolamine buffer. Data was fitted to a four parameter hyperbolic curve58.
For avidity ELISAs, standard curve ELISAs were performed as described above except following 2 h incuba-
tion of serum at room temperature plates were washed 6 times with PBS/Tween and 100 μ l 7 M urea added to 
serum wells for 10 min. Plates were then washed 6 times with PBS/Tween and the standard curve ELISA carried 
out as before. Avidity index was calculated as the percentage of log10 EU of urea-treated compared untreated 
serum samples, following the procedure described by Grangeot-Keros, L. et al.59.
For IgG subclass ELISAs, standard curve ELISAs were performed as described above, using the Biorad Mouse 
Typer Sub-Isotyping kit with these modifications (protocol for mouse typer sub-isotyping kit, Biorad): after 
serum incubation subclass-specific rabbit anti-mouse IgG was applied at 50 μ l per well in triplicate. The stand-
ard curve was incubated with kappa-chain specific IgG. After 1 h incubation plates were washed 6 times with 
PBS/Tween and goat anti-rabbit horseradish peroxidase conjugate applied (50 μ l/well, 1:3000). After 1 h plates 
were washed 6 times with PBS/Tween and developed for 14 min using 100 μ l/well peroxidase substrate solution 
(Biorad). Reactions were stopped by adding 100 μ l/well 2% oxalic acid.
Expression and purification of PvCSP VK210 and VK247 proteins. The P. vivax protein CSP210 
(Belem; GenBank accession number P08677) and the protein CSP247 (PNG; GenBank accession number 
M69059) were produced as previously described60. In addition, a chimeric CSP protein containing the repeats 
from both PvCSP210 and PvCSP247 was produced. Briefly, a codon-optimized synthetic gene (chimeric 
CSP210/247) was synthesized by GeneArtTM. CSP210/247 was subcloned into the expresion plasmid PHLsec 
(His6 tag), which is driven by the chicken β -actin/rabbit β -globin hybrid promoter61. The resulting PHLsec 
CSP210/247 was verified by DNA sequencing.
All secreted proteins were purified from media supernatants from PEI-transfected HEK-293T cells using 
roller bottles (2,125 cm2) at 37 C and 5% CO2, using immobilised metal ion affinity chromatography (IMAC) 
medium (resin) precharged with nickel ions (Ni Sepharose™ excel, GE Healthcare). Conditioned media was 
filtered through a 0.45 μ m membrane (Millipore). IMAC purification was performed using a distilled water wash 
step with 5 column volumes (CV) at a flow velocity of 100 cm/h, equilibration step with 5CV of equilibration 
buffer (20 mM sodium phosphate, 0.5 M NaCl, pH 7.4/flow velocity: 150 cm/h), load sample step (flow veloc-
ity: 150 cm/h), wash step with 20 CV of wash buffer (20 mM sodium phosphate, 0.5 M NaCl, 20 mM imidazole, 
pH 7.4/flow velocity: 150 cm/h), linear elution step with 2 CV of 7% elution buffer (20 mM sodium phosphate, 
0.5 M NaCl, 500 mM imidazole, pH 7.4/flow velocity: 150 cm/h) and 2 CV of 70% elution buffer (flow velocity: 
150 cm/h). Elution samples after IMAC purification were analysed using a 12.5% SDS-PAGE under reducing con-
ditions and proteins were visualized with Silver stain and Western Blot analyses using the monoclonal antibody 
anti PvCSP-VK 210 and VK247. (Obtained through MR4 BEI Resources NIAID, NIH: Monoclonal Antibody 
Sporozoite ELISA Kit, Anti-Plasmodium vivax Circumsporozoite Proteins, MRA-1028K, contributed by R. A. 
Wirtz). Samples were concentrated using an Amicon® Ultra centrifugal filter system (Life Technologies) until 
reaching 10 ml of final volume. Removal of possible contaminant proteins and salts was done by size exclusion 
purification (SEC). SDS-PAGE electrophoresis and subsequent Coomassie and Silver staining was performed to 
assess protein purity.
Peptides. Crude 20-mer peptides overlapping by 10 amino acids and representing full-lengths of P. vivax CSP 
VK210 and VK247 were synthesized by Mimotopes (Victoria, Australia). Individual peptide pools were used at a 
final concentration of 5 μ g/mL per peptide.
Ex-vivo IFN-γ ELISPOT assay. Ex vivo IFN-gamma (IFN-γ ) ELISPOTs were carried out using PBMCs 
isolated from the blood as previously described62,63. The assay was performed using MAIP ELISPOT plates 
(Millipore) were where PBMCs (1 × 106 cells/well) were co-cultured with splenocytes (2.5 × 105 cells/well) in 
Minimum Essential Medium Eagle supplemented with 1% L-Glutamine, 10% Foetal Calf Serum (FCS), Penicillin 
and Streptomycin (100 UI/ml). Overlapping peptide libraries consisting on 20-mer peptides overlapping by 10 
were purchased at PEPSCAN Presto, The Netherlands. Peptides spanned the whole sequence of the P. vivax CSP 
VK210 and VK247 transgenes and were used to stimulate the co-cultures for 16 hours. DMSO, phytohemagglu-
tinin (10 U/mL) and medium controls were used in the same assay plate. Anti-mouse IFN-γ mAb and devel-
opment reagents were used according to the manufacturer specifications (Mabtech). Spots were counted using 
an ELISPOT counter (Autoimmun Diagnostika (AID), Germany). Results are expressed as IFN-γ spot-forming 
units (SFU) per million PBMCs.
Infection of mice. The CD-1 and C57Bl/6 mice that were vaccinated with 0.5 μ g of Rv21 were challenged 
with 2,000 wild type or transgenic P. berghei sporozoites. When C57Bl/6 mice were vaccinated with increased 
doses of 5 μ g/mouse of Rv21, a higher dose of 5,000 sporozoites per mouse was used for a challenge. Infection was 
monitored from day 5 to 20 by Giemsa staining of blood smears.
Statistical model for parasitaemia prediction. Percent parasitaemia was used to calculate the time 
required to reach a blood-stage infection of 1% or time to 1% parasitaemia. This was predicted using a linear 
regression model as described previously25. Briefly, blood parasite counts were obtained for 3–5 consecutive days 
starting on day 5 after the challenge. Blood smears were stained with Giemsa and percentages of parasitaemia 
calculated in all animals. The logarithm to base 10 of the calculated percentage of parasitaemia was plotted against 
the time after challenge and Prism 5 for Mac OS X (GraphPad software) statistical analysis package used for gen-
erating a linear regression model on the linear part of the blood-stage growth curve.
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In vivo imaging after malaria sporozoite challenge. Bioluminescent luciferase signal was quantified by 
imaging the whole animals using the in vivo IVIS 200 imaging system (Caliper Life Sciences, USA), as described 
elsewhere36,64,65. Briefly, 44 hrs after the intravenous injection with 1000 transgenic P. berghei sporozoites the 
mice were anaesthetized in batches of three using isofluorane, their fronts shaved and D-luciferin (Synchem 
Laborgemeinschaft OHG, Germany) injected into the neck at a concentration of 100 mg/kg in sterile PBS (Sigma, 
US). Animals were imaged for 120 seconds at binning value of 8 and FVO of 12.8 cm, 8 minutes after the injection 
of D-luciferin. Mice were kept anaesthetized throughout the whole procedure. Quantification of bioluminescence 
signal was performed using Living Image 4.2 software (Caliper Life Sciences, USA). The region of interest (ROI) 
were set around the liver area of the mouse body and kept constant for all of the animals. The measurements were 
expressed as a total flux of photons per second of imaging time.
Statistical analysis. For all statistical analyses, GraphPad Prism version 5.0 for Max OS was used unless 
indicated otherwise. Prior to statistical analysis to compare two or more populations, the Kolmogorov-Smirnov 
test for normality was used to determine whether the values followed a Gaussian distribution. An unpaired t-test 
was employed to compare two normally distributed groups, whereas Mann-Whitney rank test was used for com-
paring two non-parametric groups. If more than two groups were present non-parametric data was compared 
using Kruskal-Wallis test with Dunn’s multiple comparison post-test, whereas normally distributed data were 
analyzed by one-way ANOVA with Bonferroni’s multiple comparison post-test. The effect of two variables was 
explored using two-way ANOVA with Bonferroni’s multiple comparison post-test. Correlation strength was 
tested using either Pearson’s or Spearman’s tests as indicated in the results chapters. Kaplan-Meier survival curves 
were used to represent protective efficacy to a challenge with any P. berghei parasite lines. All ELISA titres were 
also log10 transformed before analysis. The value of p < 0.05 was considered statistically significant (*p < 0.05, 
**p < 0.01, **p < 0.001, and ***p < 0.001).
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